{"id":61611,"date":"2024-11-13T00:04:51","date_gmt":"2024-11-13T00:04:51","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/11\/13\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/"},"modified":"2024-11-13T00:04:51","modified_gmt":"2024-11-13T00:04:51","slug":"calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/","title":{"rendered":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results"},"content":{"rendered":"<div>\n<ul>\n<li><em>Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.<\/em><\/li>\n<li><em>Presented data supporting RTNova (CLD-400), the company\u2019s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, California.<\/em><\/li>\n<li><em>Raised $2 million in a registered direct offering and concurrent private placement.<\/em><\/li>\n<\/ul>\n<p>SAN DIEGO, Nov.  12, 2024  (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics Inc. (NYSE American: CLDI) (\u201cCalidi\u201d), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024, and reviewed recent business highlights.<\/p>\n<p>\u201cCalidi continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies,\u201d said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. \u201cIn addition, we are pleased that Northwestern University has received U.S. FDA clearance to advance our CLD-101 program in the clinic for newly diagnosed high-grade glioma.\u201d<\/p>\n<p><strong>Third Quarter 2024 and Recent Corporate Developments<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt;\">The U.S. Food and Drug Administration (FDA) has cleared Northwestern University\u2019s Investigational New Drug (IND) application for Calidi\u2019s NeuroNova (CLD-101). CLD-101 is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors, enhancing their antitumor effects. The Phase 1b\/2 clinical trial in newly diagnosed high-grade glioma is expected to commence in early 2025 at Northwestern University.<\/li>\n<li style=\"margin-bottom:8pt;\">Data was presented on RTNova (CLD-400), Calidi\u2019s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, at Immuno US 2024 in San Diego, California and the Society for Immunotherapy of Cancer (SITC) annual meeting. RTNova is a systemic treatment designed for reduced elimination by the humoral immune system. It targets multiple tumor sites, killing tumor cells while altering the tumor immune microenvironment. This novel systemic therapeutic approach not only facilitates easier administration but also broadens the potential patient population who can benefit from this treatment.<\/li>\n<li style=\"margin-bottom:8pt;\">Calidi announced in October the completion of a definitive securities purchase agreement with certain institutional investors, raising $2 million in a registered direct offering and concurrent private placement.<\/li>\n<\/ul>\n<p><strong>Third Quarter 2024 Financial Results<\/strong><\/p>\n<p>The Company reported a net loss of $5.1 million, or $0.65 per share, for the three months ended September 30, 2024, compared to a net loss of $2.0 million, or $1.41 per share, for the same period in 2023.<\/p>\n<p>Research and development expenses were $2.2 million for the three months ended September 30, 2024, compared to $3.3 million for the comparable period in 2023, respectively.<\/p>\n<p>General and administrative expenses were $3.1 million for the three months ended September 30, 2024, compared to $4.0 million for the comparable period in 2023, respectively.<\/p>\n<p>The Company had approximately $1.9 million in cash and $0.2 million in restricted cash as of both September 30, 2024 and December 31, 2023.<\/p>\n<p><strong>About Calidi Biotherapeutics:<\/strong><\/p>\n<p>Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YoLV3hKqHIgiO1usXhR_LO876_9czNmJ8SeqGNgfOqm3R2XY_vVHaUPH75BIx5ptagkWrJCw4lQjSNP64M9yorRpbj83fHIUsFomdFo6w9KdrPWerlM860YKgstY0NPzS-Z1pNQenWWvEuKxWKr0_w_GMdkf1nNFWnl2VldRD88QvyiGXDQHuqpZwJZv0tymVTMaN4GWYGkIMvir38XOqS8ebceKBZ4jJkc8WnjVD2kIfKdwdB7XWi4H2AbUnLfH_VshmWoW-T0uiplDTCyA68TEtzwsJeI_US6nQUbRT6c9rE_vFASJqVXZ6znynWedvlX-ItIuqC8ETuYq79pSxQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>www.calidibio.com<\/strong><\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, and (iii) Form 10-Q filed on August 13, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time.<\/p>\n<p><strong><u>For Investors:<\/u><\/strong><br \/>Dave Gentry, CEO<br \/>RedChip Companies, Inc.<br \/>1-407-644-4256<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tHQTJEWp2d17TVXI32DAtY1ym6uGuviEer-9fHbhTlhlwFvstrJyjUWQISTooHLJuXvzMpHCczf2wGgz_QsisQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"CLDI@redchip.com\">CLDI@redchip.com<\/a><\/p>\n<p align=\"center\"><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>CALIDI BIOTHERAPEUTICS, INC.<\/strong><br \/><strong>CONDENSED CONSOLIDATED BALANCE SHEETS<br \/><\/strong>(<em>In thousands except for par value data<\/em>)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>September 30, 2024<\/strong><strong><br \/><\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>December 31, 2023<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<td colspan=\"2\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>(Unaudited)<\/strong><strong><br \/><\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>ASSETS<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">CURRENT ASSETS<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:72%; width:72%; min-width:72%;;vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Cash<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:11%; width:11%; min-width:11%;;padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,897<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:11%; width:11%; min-width:11%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,949<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Prepaid expenses and other current assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">324<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,354<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total current assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,221<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,303<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">NONCURRENT ASSETS<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Machinery and equipment, net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">982<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,270<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Operating lease right-of-use assets, net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">3,237<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,073<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Other noncurrent assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">217<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">373<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">TOTAL ASSETS<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">6,657<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">10,019<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">CURRENT LIABILITIES<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accounts payable<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">$<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">3,574<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">$<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,796<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party accounts payable<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">81<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accrued expenses and other current liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,567<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,896<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party accrued expenses and other current liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">496<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">536<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Term notes payable, net of discount, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">242<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">529<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party term notes payable, net of discount, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,631<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">278<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party bridge loan payable, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">217<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party other current liability<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">620<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Finance lease liability, current<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">69<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">81<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Operating lease right-of-use liability, current<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,163<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,035<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total current liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">11,579<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">10,232<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">NONCURRENT LIABILITIES<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Operating lease right-of-use liability, noncurrent<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,161<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">3,037<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Finance lease liability, noncurrent<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">166<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">216<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Warrant liability<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">163<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">623<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party warrant liability<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">13<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">48<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Convertible notes payable, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,773<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party term notes payable, net of discount, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,060<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Promissory note<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">600<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Other noncurrent liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,500<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party other noncurrent liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">538<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">TOTAL LIABILITIES<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">16,455<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">18,254<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Commitments and contingencies (Note 11)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">STOCKHOLDERS\u2019 DEFICIT<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Common stock, $0.0001 par value, 330,000 shares authorized; 9,311 and 3,552 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Additional paid-in capital<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">107,408<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">91,383<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Non-controlling interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">485<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accumulated other comprehensive loss, net of tax<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(74<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(47<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accumulated deficit<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(117,618<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(99,572<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Total stockholders\u2019 deficit<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(9,798<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(8,235<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">6,657<\/td>\n<td style=\"padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">10,019<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\"><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"14\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>CALIDI BIOTHERAPEUTICS, INC.<\/strong><br \/><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<\/strong><br \/><em>(In thousands, except per share data)<\/em><\/td>\n<\/tr>\n<tr>\n<td colspan=\"14\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<td colspan=\"7\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>Three Months Ended <\/strong><br \/><strong>September 30,<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>2024<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>2023<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \"><strong>\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"7\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>(Unaudited)<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \"><strong>OPERATING EXPENSES<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"max-width:72%; width:72%; min-width:72%;;vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Research and development<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">$<\/td>\n<td colspan=\"2\" style=\"max-width:11%; width:11%; min-width:11%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,153<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">)<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:11%; width:11%; min-width:11%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(3,251<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">General and administrative<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(3,073<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(3,970<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 25.0px; vertical-align: bottom ; \">Total operating expense<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,226<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(7,221<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \">Loss from operations<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,226<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(7,221<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \"><strong>OTHER INCOME (EXPENSES), NET<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Interest expense<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(98<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(101<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Interest expense \u2013 related party<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(134<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(223<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Change in fair value of debt, other liabilities, and derivatives<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">352<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">845<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Change in fair value of debt, other liabilities, and derivatives \u2013 related party<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">28<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,473<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Debt extinguishment<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(139<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Debt extinguishment \u2013 related party<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(332<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Grant income<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">693<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Other income (expense), net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">8<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(8<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 25.0px; vertical-align: bottom ; \">Total other income (expenses), net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">156<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">5,208<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \"><strong>LOSS BEFORE INCOME TAXES<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,070<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,013<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Income tax credit (provision)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(11<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \"><strong>NET LOSS<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td colspan=\"2\" style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,069<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,024<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Net loss attributable to noncontrolling interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(15<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \"><strong>NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td colspan=\"2\" style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,054<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,024<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Deemed dividend on warrants<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \"><strong>NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td colspan=\"2\" style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,054<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,024<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \"><strong>Net loss per share; basic and diluted<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td colspan=\"2\" style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(0.65<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(1.41<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: bottom ; \">Weighted average common shares outstanding; basic and diluted<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">7,824<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,431<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmVmNzlkMzItODkwMy00YjdlLWE0MTYtODUwMjg3MjkwNmIzLTEyMDU0MDc=\/tiny\/Calidi-Biotherapeutics-Inc.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma. Presented data supporting RTNova (CLD-400), the company\u2019s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, [&#8230;]\n","protected":false},"author":1,"featured_media":61612,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results\" \/>\n<meta property=\"og:description\" content=\"Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma. Presented data sup\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-13T00:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Calidi-Biotherapeutics-Inc.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results\",\"datePublished\":\"2024-11-13T00:04:51+00:00\",\"dateModified\":\"2024-11-13T00:04:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/\"},\"wordCount\":1276,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/\",\"name\":\"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-11-13T00:04:51+00:00\",\"dateModified\":\"2024-11-13T00:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results","og_description":"Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma. Presented data sup","og_url":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-11-13T00:04:51+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Calidi-Biotherapeutics-Inc.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results","datePublished":"2024-11-13T00:04:51+00:00","dateModified":"2024-11-13T00:04:51+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/"},"wordCount":1276,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/","url":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/","name":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-11-13T00:04:51+00:00","dateModified":"2024-11-13T00:04:51+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=61611"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61611\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/61612"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=61611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=61611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=61611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}